Skip to Content

XOMA Corp

Rating as of

Company Profile

Business Description

XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company are functioned through the United States, Europe, and the Asia Pacific. XOMA's primary source of revenue is from license and collaboration arrangements, contract services, and royalties and the majority of the revenue is generated from the United States.

Contact
2200 Powell Street, Suite 310
Emeryville, CA, 94608
T +1 510 204-7200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees 10